Plus Therapeutics (PSTV on Nasdaq) is a U.S. clinical-stage pharmaceutical company, backed by talented executives and a nationwide network of scientists, engineers and physicians.
With a hybrid virtual drug development model, we are well-positioned to be capital efficient, enhance operational efficiencies, decrease costs, and accelerate product development. We are headquartered in Houston, Texas, with additional laboratories and state-of-the-art clean rooms in order to undertake key development, manufacturing, and preclinical activities..
Our location provides us with many strategic advantages, including proximity to world-class cancer institutions and researchers – as well as the ability to qualify and apply for funding through the Cancer Prevention and Research Institute of Texas (CPRIT).
A knowledgeable and effective team that marries the proper skills with a similar mindset.
A growing suite of innovative radiotherapeutic formulations and targeted delivery technologies.
The identification of logical clinical targets with a high likelihood of FDA approval and positive patient outcomes.
The rapid advancement of our drug candidates through the development cycle in a cost-effective manner.
A set of partners with supportive technologies that increase our chance of clinical and commercial success.
Our platform is built on novel formulations comprised of beta- and gamma-energy-emitting Rhenium radionuclides, novel radioisotope loading technology such as BMEDA chelation and nanoliposomes, and biodegradable microspheres. We leverage unique combinations of these components to develop our lead product candidates, REYOBIQ™ (rhenium Re186 obisbemeda) and 188RNL-BAM. They have the potential to deliver effective, elevated doses of radiation directly to complex tumors, while sparing healthy tissue.